PriceSensitive

Telescope Innovations Corp. (CSE:TELI) launches first automation product

Technology
CSE:TELI
27 June 2022 10:00 (EDT)

Telescope Innovations (TELI) has launched Telescope Automation to accelerate chemical and biopharmaceutical research and development.

Telescope Automation has launched its first product, the Direct Inject Liquid Chromatography platform, that provides real-time, immediate analysis of chemical reactions.

The system samples batch or continuous processes and automatically quenches, dilutes, and injects the samples into a high-or ultra-performance liquid chromatography instrument.

“We have been engaged by several major global pharmaceutical companies to onboard our DILC platform,” noted Jason Hein, Telescope CEO.

“Telescope has already leveraged this enabling tool across all our operations, and we are now bringing this to market as an unrivalled capability to address an unmet need in process analytics,” he added.

This product launch enables Telescope to capture the fast-developing market opportunity for the DILC system, generate revenue, and establish the company as a partner of choice for process laboratory tool integration.

The commercial deployment and insight provided by DILC technology will highlight, at an industrial scale, the unique combination of skills. Telescope provides to support chemical, biopharmaceutical, and manufacturing process development.

Telescope is a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry.

Telescope Innovations Corp. opened the day’s trading at $0.245 per share.

Related News